Envisagenics Announces Research Collaboration with Bristol Myers Squibb

Envisagenics, an Artificial Intelligence ("AI")-driven biotechnology company that delivers therapies for RNA splicing diseases, today announced a research collaboration agreement with Bristol-Myers Squibb (NYSE: BMY).